Notably, previous reports have shown that azelastine strongly inhibited colorectal cancer cell proliferation and mitochondrial fission both in vitro and in vivo by directly targeting ADP-ribosylation factor 1 (ARF1), thereby interfering with downstream oncogenic signaling (IQGAP1–ERK–Drp1 pathway) and it induces anticancer effects through ARF1 targeting in colorectal cancer cells [16,17]. Here, ARF1 is linked to colorectal cancer.